These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 15939261)

  • 1. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
    Cooper R; Kaanders JH
    Eur J Cancer; 2005 Jun; 41(9):1261-6. PubMed ID: 15939261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microbiologic surrogate end points in clinical trials of infectious diseases: example of acute otitis media trials.
    Powers JH
    Pharmacotherapy; 2005 Dec; 25(12 Pt 2):109S-123S. PubMed ID: 16305280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. End points in cancer clinical trials and the drug approval process.
    Schilsky RL
    Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate end points in clinical research: hazardous to your health.
    Grimes DA; Schulz KF
    Obstet Gynecol; 2005 May; 105(5 Pt 1):1114-8. PubMed ID: 15863552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A clinical development paradigm for cancer vaccines and related biologics.
    Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
    J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The evaluation of the results of clinical trials: surrogate end points and composite end points.
    Gensini GF; Conti AA
    Minerva Med; 2004 Feb; 95(1):71-5. PubMed ID: 15041928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy.
    Tang PA; Bentzen SM; Chen EX; Siu LL
    J Clin Oncol; 2007 Oct; 25(29):4562-8. PubMed ID: 17876010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.
    Burzykowski T; Buyse M; Piccart-Gebhart MJ; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1987-92. PubMed ID: 18421050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Achieving treatment goals for hormone-refractory prostate cancer with chemotherapy.
    Berry W; Eisenberger M
    Oncologist; 2005; 10 Suppl 3():30-9. PubMed ID: 16368869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals.
    Collette L; Burzykowski T; Carroll KJ; Newling D; Morris T; Schröder FH; ; ;
    J Clin Oncol; 2005 Sep; 23(25):6139-48. PubMed ID: 16135480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The promise and peril of surrogate end points in cancer research.
    Schatzkin A; Gail M
    Nat Rev Cancer; 2002 Jan; 2(1):19-27. PubMed ID: 11902582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A; Pandha H
    Adv Cancer Res; 2007; 96():175-90. PubMed ID: 17161680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harnessing preclinical mouse models to inform human clinical cancer trials.
    Gutmann DH; Hunter-Schaedle K; Shannon KM
    J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value, qualification, and regulatory use of surrogate end points in drug development.
    Lathia CD; Amakye D; Dai W; Girman C; Madani S; Mayne J; MacCarthy P; Pertel P; Seman L; Stoch A; Tarantino P; Webster C; Williams S; Wagner JA
    Clin Pharmacol Ther; 2009 Jul; 86(1):32-43. PubMed ID: 19474783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surrogate end points in cancer research: a critique.
    Schatzkin A; Freedman LS; Dorgan J; McShane LM; Schiffman MH; Dawsey SM
    Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):947-53. PubMed ID: 8959315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers in early cancer drug development: limited utility.
    Glassman RH; Ratain MJ
    Clin Pharmacol Ther; 2009 Feb; 85(2):134-5. PubMed ID: 19151638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
    Gill S; Sargent D
    Oncologist; 2006 Jun; 11(6):624-9. PubMed ID: 16794241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical benefit in oncology trials: is this a patient-centred or tumour-centred end-point?
    Ohorodnyk P; Eisenhauer EA; Booth CM
    Eur J Cancer; 2009 Sep; 45(13):2249-52. PubMed ID: 19545996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ["Soft" and "hard" end points in the example of hypertension].
    Düsing R
    Dtsch Med Wochenschr; 2006 May; 131(19 Suppl 1):S21-6. PubMed ID: 16688661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.